AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Osteoporosis: Etidronic acid is used to prevent and treat osteoporosis, a condition characterized by reduced bone density and increased risk of fractures. By inhibiting bone resorption (breakdown), etidronic acid helps maintain bone mass and reduce the risk of fractures in individuals with osteoporosis.
Management of Paget's Disease: Etidronic acid is also indicated for the treatment of Paget's disease of bone, a chronic bone disorder characterized by abnormal bone remodeling. It helps regulate bone turnover and reduce the excessive bone resorption and formation seen in Paget's disease, thereby improving bone structure and reducing symptoms such as bone pain and deformity.
Mechanism of Action: Etidronic acid exerts its pharmacological effects by binding to hydroxyapatite crystals in bone and inhibiting osteoclast-mediated bone resorption. By interfering with the activity of osteoclasts, the cells responsible for breaking down bone tissue, etidronic acid helps maintain bone density and strength.
Administration and Dosage: Etidronic acid is typically administered orally in the form of tablets or intravenously as an infusion. The dosage and duration of treatment may vary depending on the specific indication, severity of the condition, and individual patient factors. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional.
Adverse Effects: Common side effects of etidronic acid may include gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea. Long-term use of bisphosphonates like etidronic acid has been associated with rare but serious adverse effects, including osteonecrosis of the jaw (ONJ) and atypical femoral fractures. Patients should be monitored for these potential complications, especially with prolonged therapy.
Contraindications: Etidronic acid is contraindicated in individuals with hypersensitivity to bisphosphonates or any of its components. It should also be used with caution in patients with renal impairment, as dose adjustments may be necessary to prevent accumulation of the drug and potential renal toxicity.
Drug Interactions: Etidronic acid may interact with other medications, including calcium supplements, antacids, and certain antibiotics, leading to reduced absorption or efficacy. It is important to inform healthcare providers about all medications, supplements, and herbal products being taken concurrently with etidronic acid to minimize the risk of drug interactions.
Monitoring: Patients receiving etidronic acid therapy may require regular monitoring of renal function, bone mineral density, and serum calcium levels to assess treatment response and detect any potential adverse effects or complications.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| unclassified Robinsoniella | no rank | Decreases | ⚗️ Source Study | |
| unclassified Fusobacterium | no rank | Decreases | ⚗️ Source Study | |
| unclassified Negativicoccus | no rank | Decreases | ⚗️ Source Study | |
| Eggerthellales | order | Decreases | ⚗️ Source Study | |
| Anaerofustis stercorihominis | species | Decreases | ⚗️ Source Study | |
| Asaccharospora irregularis | species | Decreases | ⚗️ Source Study | |
| Negativicoccus sp. S5-A15 | species | Decreases | ⚗️ Source Study | |
| Paraprevotella clara | species | Decreases | ⚗️ Source Study | |
| Slackia sp. NATTS | species | Decreases | ⚗️ Source Study | |
| Pseudoflavonifractor capillosus | species | Decreases | ⚗️ Source Study | |
| [Collinsella] massiliensis | species | Decreases | ⚗️ Source Study | |
| Parvibacter caecicola | species | Decreases | ⚗️ Source Study | |
| Coriobacterineae | suborder | Decreases | ⚗️ Source Study | |
| Chlamydiae/Verrucomicrobia group | superphylum | Decreases | ⚗️ Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Chronic Fatigue Syndrome | 0.1 | 0.1 | |
| Depression | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Mood Disorders | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.